Humacyte (HUMA) Cash from Financing Activities (2020 - 2026)
Humacyte (HUMA) posted quarterly Cash from Financing Activities of $23.3 million for Q1 2026, down 50.1% year-over-year from $46.7 million in Q1 2025, and down 59.21% quarter-over-quarter from $57.2 million in Q4 2025.
Humacyte (HUMA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Cash from Financing Activities for 7 consecutive years, with $23.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 50.1% year-over-year to $23.3 million; the TTM figure through Mar 2026 stood at $38.1 million (down 61.21% YoY), while the FY2025 annual figure was $61.5 million, down 46.15% from the prior year.
- Cash from Financing Activities fell to $23.3 million in Q1 2026 per HUMA's latest filing, from $57.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $62.8 million in Q1 2024 and bottomed at -$44.6 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $11.9 million across 5 years, with a median of -$212000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 15453.3% — and 2025, when it tumbled 5352.18%.
- Humacyte's Cash from Financing Activities stood at -$212000.0 in 2022, then tumbled by 58.02% to -$335000.0 in 2023, then surged by 15325.67% to $51.0 million in 2024, then rose by 12.09% to $57.2 million in 2025, then slumped by 59.21% to $23.3 million in 2026.
- Business Quant data shows HUMA's Cash from Financing Activities at $23.3 million in Q1 2026, $57.2 million in Q4 2025, and -$44.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | 53.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.53 Mn |
| Jun 30, 2026 | 53.53 Mn |
| Mar 31, 2026 | 23.32 Mn |
| Mar 31, 2026 | 23.32 Mn |
| Dec 31, 2025 | 57.17 Mn |
| Dec 31, 2025 | 57.17 Mn |
| Sep 30, 2025 | -44.59 Mn |
| Sep 30, 2025 | -44.59 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 46.74 Mn |
| Mar 31, 2025 | 46.74 Mn |
| Dec 31, 2024 | 51.01 Mn |
| Dec 31, 2024 | 51.01 Mn |
| Sep 30, 2024 | 849,000.00 |
| Sep 30, 2024 | 849,000.00 |
| Jun 30, 2024 | -467,000.00 |
| Jun 30, 2024 | -467,000.00 |
| Mar 31, 2024 | 62.80 Mn |
| Mar 31, 2024 | 62.80 Mn |